Novel p53 splice site mutations in three families with Li-Fraumeni syndrome

被引:24
|
作者
Verselis, SJ
Rheinwald, JG
Fraumeni, JF
Li, FP [1 ]
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA
[4] Harvard Univ, Brigham & Womens Hosp, Sch Med, Skin Dis Res Ctr, Boston, MA 02115 USA
[5] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
关键词
p53; germline mutation; Li-Fraumeni syndrome; alternate splicing;
D O I
10.1038/sj.onc.1203758
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germline mutations in the p53 tumor suppressor gene predispose to a variety of cancers in families with Li-Fraumeni syndrome. Most germline p53 mutations observed to date cause amino acid substitutions in the protein's central sequence-specific DNA binding domain. Outside this conserved core region, however, we found novel alterations in sequences that regulate precursor mRNA splicing in three Li-Fraumeni syndrome families. Two splice site mutations affected the consensus sequence at the splice donor sites of introns 1 and 9, and produced unstable variant transcripts in normal cells. A third mutation at the splice acceptor site of intron 9 generated splicing at a cryptic acceptor site in intron 9, These splice site alterations emphasize the need to examine both noncoding and untranslated regions of the p53 gene for germline mutations in Li-Fraumeni syndrome families.
引用
收藏
页码:4230 / 4235
页数:6
相关论文
共 50 条
  • [41] Mutant p53 regulation in a Li-Fraumeni mouse model
    Terzian, Tamara
    Plehaty, Molly
    Sobhani, Nema
    Stevens, Wanida
    Marasligiller, Stefan
    Srinivas, Tara
    Mylavarapu, Rohan
    Clarke, Yvonne
    Arbab, Farinaz
    Podell, Brendon
    Bronson, Roderick
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome
    Fischer, Nicholas W.
    Prodeus, Aaron
    Tran, James
    Malkin, David
    Gariepy, Jean
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (12): : 1418 - 1421
  • [43] Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility
    Akashi, M
    Koeffler, HP
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1998, 41 (01): : 172 - 199
  • [44] Potential of Advexin®: a p53 gene-replacement therapy in Li-Fraumeni syndrome
    Nemunaitis, Jackie M.
    Nemunaitis, John
    FUTURE ONCOLOGY, 2008, 4 (06) : 759 - 768
  • [45] Germline p53 mutation in a case of Li-Fraumeni syndrome presenting gastric cancer
    Sugano, K
    Taniguchi, T
    Saeki, M
    Tsunematsu, Y
    Tomaru, U
    Shimoda, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (10) : 513 - 516
  • [46] COLLABORATIVE INTERDISCIPLINARY STUDIES OF P53 AND OTHER PREDISPOSING GENES IN LI-FRAUMENI SYNDROME
    LI, FP
    FRAUMENI, JF
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1994, 3 (08) : 715 - 717
  • [47] p53 codon 72 polymorphism and cancer risk in Li-Fraumeni syndrome.
    Yip, L
    Hwang, SJ
    Strong, LC
    Lozano, G
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 471 - 471
  • [48] Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
    Olive, KP
    Tuveson, DA
    Ruhe, ZC
    Yin, B
    Willis, NA
    Bronson, RT
    Crowley, D
    Jacks, T
    CELL, 2004, 119 (06) : 847 - 860
  • [49] Novel p53 splicing site mutation in Li-Fraumeni-like syndrome with osteosarcoma
    Sakurai, Naoto
    Iwamoto, Shotaro
    Miura, Yoshihiro
    Nakamura, Tomoki
    Matsumine, Akihiko
    Nishioka, Junji
    Nakatani, Kaname
    Komada, Yoshihiro
    PEDIATRICS INTERNATIONAL, 2013, 55 (01) : 107 - 111
  • [50] Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10
    Stone, JG
    Eeles, RA
    Sodha, N
    Murday, V
    Sheriden, E
    Houlston, RS
    CANCER LETTERS, 1999, 147 (1-2) : 181 - 185